OCSL — Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corporation (OCSL) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Net Investment Income: $35.4 million, or $0.40 per share, up from $32.5 million, or $0.37 per share in Q3 2025.
• Net Asset Value (NAV): $16.64 per share, down from $16.76 in the previous quarter due to unrealized depreciation on investments.
• Total Investment Income: Increased to $76.9 million from $74.3 million in Q3, driven by higher prepayment fees and dividend income.
• Interest Expense: Decreased due to refinancing and lower reference rates, with a weighted average cost of borrowings at 6.5%.
• Leverage Ratio: 0.97 times, slightly up from 0.93 times in the prior quarter.
• Liquidity: Approximately $695 million available, including $80 million in cash and $615 million in undrawn credit capacity.

2. Strategic Updates and Business Highlights

• Nonaccruals: Reduced to 2.8% of the portfolio, down from 3.8% a year ago, indicating progress in resolving troubled investments.
• Investment Activity: Funded investment commitments of $120 million, up 54% from the prior quarter, with a focus on senior secured loans.
• Portfolio Composition: 83% of the portfolio is first lien senior secured debt, with a weighted average yield of 9.8%.
• Notable Investment: A $2.5 billion term loan to Walgreens Boots Alliance, highlighting OCSL's ability to handle complex transactions.

3. Forward Guidance and Outlook

• Market Environment: While private credit deal flow has improved, the quality of deals is mixed. The company remains cautious about new investments due to tighter spreads.
• Future Earnings: Anticipated impacts from lower base rates on net investment income, but management has several levers to mitigate this, including increasing leverage and optimizing joint ventures.

4. Challenges and Points of Concern

• Declining NAV: The decrease in NAV per share indicates potential headwinds from unrealized losses.
• Nonaccruals in Healthcare and Pharma: Continued challenges in the life sciences sector, with several large positions still in workout status, which may weigh on future performance.
• Market Competition: Heightened competition and tighter spreads may limit the ability to secure high-yield investments.

5. Notable Q&A Insights

• Investment Activity Expectations: Management does not foresee significant outsized repayments or deviations from typical deployment patterns in the upcoming December quarter.
• Pipeline for Complex Transactions: While the Walgreens deal was notable for its high spread, management does not expect similar opportunities in the near term, indicating a cautious approach to new investments.
• Operational Workouts: Ongoing efforts to improve performance in long-standing nonaccruals, with a focus on operational turnarounds rather than new capital structure adjustments.

Overall, OCSL demonstrated solid financial performance in Q4 2025, with improvements in income and a reduction in nonaccruals. However, challenges remain in the form of declining NAV and ongoing issues in specific sectors, necessitating a careful approach to future investments.